Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

NCT03139370 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT03139370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Terminated
Start date
December 27, 2017
Completion date
June 4, 2023
Enrollment
16 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor